Why Is Netflix Stock Falling on Monday?
Netflix Inc. (NASDAQ: NFLX) stock slips as market concerns over third-quarter revenue and earnings guidance outweigh Bill Ackman's new Pershing Square stake.
Read original at benzingaStocks · News reference
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bill Ackman’s New Stock Picks Are Here. These ETFs Could Be Worth Watching
Bill Ackman's new stock picks include Netflix, Visa and Mastercard. ETF investors can get fresh exposure through VFH, XLC and IAI.
Read original at benzingaHow BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.
Read original at zacks-investment-researchBridgeBio Pharma Announces Late-Breaking Oral Presentation Of Phase 3 PROPEL 3 Data On Oral Infigratinib In Achondroplasia At ESPE 2026 On September 9
Read original at benzingaHC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
Read original at benzingaMizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110
Read original at benzinga